| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/SREP18494 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/srep18494 |
| P932 | PMC publication ID | 4683444 |
| P698 | PubMed publication ID | 26678097 |
| P5875 | ResearchGate publication ID | 287583666 |
| P50 | author | Joaquín Dopazo | Q31034660 |
| Enrique Vidal | Q41536859 | ||
| Alicia Amadoz | Q41723837 | ||
| P2093 | author name string | Patricia Sebastian-Leon | |
| Francisco Salavert | |||
| P2860 | cites work | Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). | Q53390153 |
| Bioconductor: open software development for computational biology and bioinformatics | Q21194861 | ||
| Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 | ||
| The Reactome pathway knowledgebase | Q24567743 | ||
| Data, information, knowledge and principle: back to metabolism in KEGG | Q24568332 | ||
| RNA-Seq: a revolutionary tool for transcriptomics | Q24596169 | ||
| Systems pharmacology: network analysis to identify multiscale mechanisms of drug action | Q26824166 | ||
| Identification of aberrant pathways and network activities from high-throughput data | Q26829854 | ||
| The ErbB/HER family of protein-tyrosine kinases and cancer | Q28302611 | ||
| Repeatability of published microarray gene expression analyses | Q28307780 | ||
| Utilization of genomic signatures to identify phenotype-specific drugs | Q28476014 | ||
| The Connectivity Map: a new tool for biomedical research | Q28530408 | ||
| Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway | Q28534009 | ||
| A network flow-based method to predict anticancer drug sensitivity | Q28547323 | ||
| affy--analysis of Affymetrix GeneChip data at the probe level | Q29547353 | ||
| Network medicine: a network-based approach to human disease | Q29547462 | ||
| The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease | Q29547614 | ||
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 | ||
| Systematic identification of genomic markers of drug sensitivity in cancer cells | Q29547695 | ||
| Ten years of pathway analysis: current approaches and outstanding challenges | Q29615564 | ||
| Interactome networks and human disease | Q29615773 | ||
| An integrative genomics approach to infer causal associations between gene expression and disease | Q29616385 | ||
| A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery | Q30443764 | ||
| The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models | Q30512428 | ||
| Babelomics 5.0: functional interpretation for new generations of genomic data. | Q30937737 | ||
| Identification of drug-specific pathways based on gene expression data: application to drug induced lung injury | Q30941816 | ||
| The evolution of molecular biology into systems biology. | Q51602866 | ||
| Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. | Q53302291 | ||
| CEBS--Chemical Effects in Biological Systems: a public data repository integrating study design and toxicity data with microarray and proteomics data. | Q31134298 | ||
| Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism | Q33264052 | ||
| Identification of key processes underlying cancer phenotypes using biologic pathway analysis | Q33283999 | ||
| A chemical and phosphoproteomic characterization of dasatinib action in lung cancer | Q33742159 | ||
| Chemosensitivity prediction by transcriptional profiling | Q33943845 | ||
| Pathway-based evaluation in early onset colorectal cancer suggests focal adhesion and immunosuppression along with epithelial-mesenchymal transition | Q34229772 | ||
| Understanding disease mechanisms with models of signaling pathway activities. | Q34422921 | ||
| An investigation of biomarkers derived from legacy microarray data for their utility in the RNA-seq era | Q34460312 | ||
| Predicting in vitro drug sensitivity using Random Forests | Q34480086 | ||
| Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer | Q34596148 | ||
| Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor | Q35234141 | ||
| Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth | Q35928707 | ||
| A systems biology approach for pathway level analysis | Q36004656 | ||
| Prediction of human population responses to toxic compounds by a collaborative competition | Q36056166 | ||
| An argument for mechanism-based statistical inference in cancer. | Q36182146 | ||
| Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. | Q36247123 | ||
| Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database | Q36629988 | ||
| Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients | Q36671291 | ||
| Rationale and clinical results of multi-target treatments in oncology. | Q36829711 | ||
| Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition | Q36905632 | ||
| Inferring the functional effect of gene expression changes in signaling pathways. | Q36954066 | ||
| Comparison and validation of genomic predictors for anticancer drug sensitivity | Q37039879 | ||
| The insulin-like growth factor pathway in lung cancer | Q37231655 | ||
| A novel signaling pathway impact analysis. | Q37319638 | ||
| Molecular networks as sensors and drivers of common human diseases | Q37594580 | ||
| Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. | Q37596249 | ||
| Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy | Q37870482 | ||
| A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia | Q38029359 | ||
| Genomics and transcriptomics in drug discovery | Q38115030 | ||
| Emerging signaling pathways in hepatocellular carcinoma. | Q38155507 | ||
| Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics. | Q38420747 | ||
| Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. | Q38466630 | ||
| Understanding cellular function and disease with comparative pathway analysis | Q38646518 | ||
| Systems biology and the future of medicine | Q38647215 | ||
| Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs | Q39066320 | ||
| Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro | Q39068761 | ||
| Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib | Q39136014 | ||
| CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. | Q39158412 | ||
| Tumor suppressor BLU promotes paclitaxel antitumor activity by inducing apoptosis through the down-regulation of Bcl-2 expression in tumorigenesis | Q39158623 | ||
| Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases | Q39180227 | ||
| Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3β-dependent protein degradation | Q39184863 | ||
| Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status | Q39319816 | ||
| Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells | Q39386176 | ||
| Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma | Q39486469 | ||
| PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways | Q39615186 | ||
| A sub-pathway-based approach for identifying drug response principal network | Q39615546 | ||
| Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib | Q39700483 | ||
| In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. | Q39701114 | ||
| Microtubule-mediated NF-kappaB activation in the TNF-alpha signaling pathway | Q39803323 | ||
| The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells | Q39837550 | ||
| Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. | Q39846889 | ||
| Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways | Q40302272 | ||
| EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells. | Q40478413 | ||
| Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells | Q40736468 | ||
| Along signal paths: an empirical gene set approach exploiting pathway topology. | Q41431283 | ||
| Signaling pathways activation profiles make better markers of cancer than expression of individual genes. | Q41874902 | ||
| Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 | ||
| Outcome signature genes in breast cancer: is there a unique set? | Q42633433 | ||
| Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro | Q42709816 | ||
| Prediction model of potential hepatocarcinogenicity of rat hepatocarcinogens using a large-scale toxicogenomics database | Q42729239 | ||
| Analysis of gene sets based on the underlying regulatory network | Q42790547 | ||
| AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. | Q43184161 | ||
| Systems diagnostics: anticipating the next generation of diagnostic tests based on mechanistic insight into disease | Q43607881 | ||
| PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy | Q44727677 | ||
| Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway | Q45108177 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | affy | Q113334509 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 18494 | |
| P577 | publication date | 2015-12-18 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity | |
| P478 | volume | 5 |
| Q57837744 | A comparison of mechanistic signaling pathway activity analysis methods |
| Q41723803 | Actionable pathways: interactive discovery of therapeutic targets using signaling pathway models |
| Q39945009 | Chronic subordination stress selectively downregulates the insulin signaling pathway in liver and skeletal muscle but not in adipose tissue of male mice |
| Q57837743 | Differential metabolic activity and discovery of therapeutic targets using summarized metabolic pathway models |
| Q64039986 | Differential metabolic activity and discovery of therapeutic targets using summarized metabolic pathway models |
| Q64099093 | FoPA: identifying perturbed signaling pathways in clinical conditions using formal methods |
| Q112294186 | Genome-scale mechanistic modeling of signaling pathways made easy: A bioconductor/cytoscape/web server framework for the analysis of omic data |
| Q42117770 | High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes. |
| Q55017642 | PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data. |
| Q59336758 | The poly-omics of ageing through individual-based metabolic modelling |
| Q91933694 | Using mechanistic models for the clinical interpretation of complex genomic variation |
| Q36051062 | Web-based network analysis and visualization using CellMaps |
Search more.